With Mod­er­na shares fly­ing at a pan­dem­ic high, the mar­ket cap has now pierced the $100B mark, leapfrog­ging Glax­o­SmithK­line

Back just be­fore the pan­dem­ic hit the world in ear­ly 2020, Mod­er­na’s shares were trad­ing right around $20 a share. To­day, it’s above $250 a share — up 3% this morn­ing — and the mar­ket cap has pierced the $100 bil­lion mark.

Work­ing so­lo, the biotech high fly­er has changed the world and saved lives with its high­ly ef­fec­tive and ap­par­ent­ly safe vac­cine for Covid-19, de­vel­oped in record time. And that’s been worth a val­u­a­tion that’s close to twice that of the oth­er big mR­NA suc­cess sto­ry: BioN­Tech, which is part­nered with an un­abashed­ly tri­umphant Pfiz­er. The Big Phar­ma part­ner has shared the prof­its and the glo­ry with BioN­Tech, which has seen its own share price soar from around $30 to $217.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE